Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis

Dupilumab (DUP) is the first biological agent used treating atopic dermatitis (AD). Notwithstanding its high cost, the type of patient group for which the drug is effective remains unclear. In this retrospective study, we aimed to identify novel and reliable biomarkers which can be measured before D...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyamoto, Shoko, Imai, Yasutomo, Matsutani, Masako, Nagai, Makoto, Yamanishi, Kiyofumi, Kanazawa, Nobuo, Nishiumi, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632056/
https://www.ncbi.nlm.nih.gov/pubmed/37946797
http://dx.doi.org/10.1155/2023/9013756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632056/
https://www.ncbi.nlm.nih.gov/pubmed/37946797
http://dx.doi.org/10.1155/2023/9013756

Ejemplares similares